Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

National Trends in Otitis Media in Children Under 5 Years of Age

Completed

Conditions: Trauma
Otitis Media
Skin Rash
Myringotomy Tube Insertion

Interventions: Other: no intervention

First Posted Date: 2011-04-20

Last Posted Date: 2023-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT01339546

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: 300 mg PF-04991532
Drug: Placebo
Drug: Sitagliptin 100 mg
Drug: 25 mg PF-04991532
Drug: 75 mg PF-04991532
Drug: 150 mg PF-04991532

First Posted Date: 2011-04-20

Last Posted Date: 2013-04-23

Lead Sponsor: Pfizer

Target Recruit Count: 301

Registration Number: NCT01338870

Locations: 🇨🇳
Pfizer Investigational Site, Taoyuan County, Taiwan

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Phase 1

Completed

Conditions: Solid Tumor
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: BEZ235 + MEK162

First Posted Date: 2011-04-19

Last Posted Date: 2020-10-09

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT01337765

Locations: 🇺🇸
Massachusetts General Hospital Mass General 2, Boston, Massachusetts, United States
🇺🇸
University of Texas/MD Anderson Cancer Center MD Anderson PSC, Houston, Texas, United States
🇪🇸
Pfizer Investigative Site, Barcelona, Cataluña, Spain

Asian Phase I Study Of PF-03446962

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: PF-03446962

First Posted Date: 2011-04-18

Last Posted Date: 2015-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT01337050

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇰🇷
Seoul National University Hospital/Department of Internal Medicine, Seoul, Korea, Republic of

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes, Type 2

Interventions: Drug: Placebo
Drug: 150 mg PF-04991532
Drug: 450 mg PF-04991532
Drug: 750 mg PF-04991532
Drug: Sitagliptin 100 mg

First Posted Date: 2011-04-18

Last Posted Date: 2013-08-06

Lead Sponsor: Pfizer

Target Recruit Count: 266

Registration Number: NCT01336738

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B

Phase 3

Completed

Conditions: Hemophilia B

Interventions: Biological: Nonacog alfa

First Posted Date: 2011-04-13

Last Posted Date: 2015-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT01335061

Locations: 🇧🇬
UMBAL Sveti Georgi, Klinika po hematologia, Plovdiv, Bulgaria
🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇰🇷
Eulji University Hospital, Daejeon, Korea, Republic of

and more 14 locations

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Phase 2

Completed

Conditions: Repevax
rLP2086
Meningitis
Meningococcal Vaccine
N Meningitidis Serogroup B

Interventions: Biological: rLP2086
Biological: Saline
Biological: Repevax

First Posted Date: 2011-03-25

Last Posted Date: 2022-10-27

Lead Sponsor: Pfizer

Target Recruit Count: 753

Registration Number: NCT01323270

Locations: 🇫🇮
Järvenpää Vaccine Research Clinic, Järvenpää, Finland
🇫🇮
Tampere Vaccine Research Clinic, Tampere, Finland
🇵🇱
Gabinet Lekarski, Debica, Poland

and more 33 locations

Risk of Cancer Among Pantoprazole Users

Completed

Conditions: Esophagitis

Interventions: Other: Does not apply

First Posted Date: 2011-03-24

Last Posted Date: 2014-02-20

Lead Sponsor: Pfizer

Target Recruit Count: 61864

Registration Number: NCT01322633

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: PH-797804
Drug: Placebo

First Posted Date: 2011-03-23

Last Posted Date: 2013-07-11

Lead Sponsor: Pfizer

Target Recruit Count: 377

Registration Number: NCT01321463

Locations: 🇬🇧
Pfizer Investigational Site, Glasgow, United Kingdom

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Phase 2

Completed

Conditions: BRAF or NRAS Mutant Metastatic Melanoma

Interventions: Drug: MEK162

First Posted Date: 2011-03-22

Last Posted Date: 2024-01-24

Lead Sponsor: Pfizer

Target Recruit Count: 183

Registration Number: NCT01320085

Locations: 🇳🇱
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Noord-holland, Netherlands
🇮🇹
Istituto nazionale Per la Ricerca sul Cancro, Genova, Italy
🇩🇪
LMU Klinikum der Universität, Muenchen, Bayern, Germany

and more 18 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy